309 related articles for article (PubMed ID: 25608583)
21. Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.
Curran A; Gutirerrez M; Deig E; Mateo G; Lopez RM; Imaz A; Crespo M; Ocaña I; Domingo P; Ribera E
J Antimicrob Chemother; 2010 Oct; 65(10):2195-203. PubMed ID: 20713406
[TBL] [Abstract][Full Text] [Related]
22. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART.
Lambert-Niclot S; George EC; Pozniak A; White E; Schwimmer C; Jessen H; Johnson M; Dunn D; Perno CF; Clotet B; Plettenberg A; Blaxhult A; Palmisano L; Wittkop L; Calvez V; Marcelin AG; Raffi F;
J Antimicrob Chemother; 2016 Apr; 71(4):1056-62. PubMed ID: 26702926
[TBL] [Abstract][Full Text] [Related]
23. Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir.
Chokephaibulkit K; Nuntarukchaikul M; Phongsamart W; Wittawatmongkol O; Lapphra K; Vanprapar N; Cressey TR
J Antimicrob Chemother; 2012 Dec; 67(12):2927-31. PubMed ID: 22923483
[TBL] [Abstract][Full Text] [Related]
24. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Sayon S; Morand-Joubert L; Delaugerre C; Algarte-Genin M; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2012 Jun; 67(6):1470-4. PubMed ID: 22396434
[TBL] [Abstract][Full Text] [Related]
25. Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration.
Croteau D; Rossi SS; Best BM; Capparelli E; Ellis RJ; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur J; McCutchan JA; Morgello S; Simpson DM; Grant I; Letendre S;
J Antimicrob Chemother; 2013 Mar; 68(3):684-9. PubMed ID: 23143899
[TBL] [Abstract][Full Text] [Related]
26. Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment - any impact of residual viremia on treatment success?
Ripamonti D; Hill A; Lauthouwers E; van Delft Y; Moecklinghoff C
AIDS Rev; 2013; 15(4):230-6. PubMed ID: 24322383
[TBL] [Abstract][Full Text] [Related]
27. Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation.
Sahloff EG; Duggan JM
Ann Pharmacother; 2019 Jan; 53(1):50-55. PubMed ID: 30047788
[TBL] [Abstract][Full Text] [Related]
28. Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia.
Seang S; Schneider L; Nguyen T; Lê MP; Soulie C; Calin R; Caby F; Valantin MA; Tubiana R; Assoumou L; Marcelin AG; Peytavin G; Katlama C
J Antimicrob Chemother; 2018 Feb; 73(2):490-493. PubMed ID: 29216346
[TBL] [Abstract][Full Text] [Related]
29. 96-week results of a dual therapy with darunavir/ritonavir plus rilpivirine once a day
Di Cristo V; Adorni F; Maserati R; Annovazzi Lodi M; Bruno G; Maggi P; Volpe A; Vitiello P; Abeli C; Bonora S; Ferrara M; Cossu MV; Oreni ML; Colella E; Rusconi S
HIV Res Clin Pract; 2020 Feb; 21(1):34-43. PubMed ID: 32129161
[TBL] [Abstract][Full Text] [Related]
30. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
J Antimicrob Chemother; 2018 Aug; 73(8):2120-2128. PubMed ID: 29905808
[TBL] [Abstract][Full Text] [Related]
32. A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).
Mussini C; Roncaglia E; Borghi V; Rusconi S; Nozza S; Cattelan AM; Segala D; Bonfanti P; Di Biagio A; Barchi E; Focà E; Degli Antoni A; Bonora S; Francisci D; Limonta S; Antinori A; D'Ettorre G; Maggiolo F
PLoS One; 2019; 14(9):e0222650. PubMed ID: 31560700
[TBL] [Abstract][Full Text] [Related]
33. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
Ruane PJ; Brinson C; Ramgopal M; Ryan R; Coate B; Cho M; Kakuda TN; Anderson D;
HIV Med; 2015 May; 16(5):288-96. PubMed ID: 25585528
[TBL] [Abstract][Full Text] [Related]
34. Cerebrospinal fluid drug concentrations and viral suppression in HIV-1-infected patients receiving ritonavir-boosted atazanavir plus lamivudine dual antiretroviral therapy (Spanish HIV/AIDS Research Network, PreEC/RIS 39).
Imaz A; Niubó J; Amara A; Khoo S; Ferrer E; Tiraboschi JM; Acerete L; Garcia B; Vila A; Podzamczer D
J Neurovirol; 2018 Aug; 24(4):391-397. PubMed ID: 29542028
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
[TBL] [Abstract][Full Text] [Related]
36. Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.
Lathouwers E; De La Rosa G; Van de Casteele T; Baeten B; Tomaka F; De Meyer S; Picchio G
Antivir Ther; 2013; 18(3):289-300. PubMed ID: 23558157
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
Flynn P; Komar S; Blanche S; Giaquinto C; Noguera-Julian A; Welch S; Lathouwers E; Van de Casteele T; Kakuda TN; Opsomer M
Pediatr Infect Dis J; 2014 Sep; 33(9):940-5. PubMed ID: 25361024
[TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once daily.
Tiraboschi JM; Knobel H; Imaz A; Villar J; Ferrer E; Saumoy M; González A; Rozas N; Vila A; Niubó J; Curto J; Podzamczer D
Antivir Ther; 2016; 21(4):359-63. PubMed ID: 26656921
[TBL] [Abstract][Full Text] [Related]
39. Tenofovir plasma concentrations related to estimated glomerular filtration rate changes in first-line regimens in African HIV-infected patients: ANRS 12115 DAYANA substudy.
Lê MP; Landman R; Koulla-Shiro S; Charpentier C; Sow PS; Diallo MB; Ngom Gueye NF; Ngolle M; Le Moing V; Eymard-Duvernay S; Benalycherif A; Delaporte E; Girard PM; Peytavin G;
J Antimicrob Chemother; 2015 May; 70(5):1517-21. PubMed ID: 25583749
[TBL] [Abstract][Full Text] [Related]
40. Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight).
Molina JM; Gallien S; Chaix ML; El Abbassi EM; Madelaine I; Katlama C; Valin N; Delobel P; Desseaux K; Peytavin G; Saillard J; Raffi F; Chevret S;
J Antimicrob Chemother; 2018 Aug; 73(8):2129-2136. PubMed ID: 29860402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]